CSL

CompanyAustraliaFounded 1994

Wikidata

CSL develops one asset. Mostly antibody acting on CLDN1; based in Australia, founded in 1994.

1
Asset
Furthest stage
Not known
1
Trial
1
Signal

Pipeline

1
  • lixudebart

    Monoclonal antibody targeting Claudin-1

    Stage not known, Antibody, CLDN1, Partner

Full company profiles: pipeline, trials, funding and people.

See Pro

Subsidiaries

1

In the full profile

  • Evidence behind the mechanisms1
  • Trials2
  • Signals1
  • Similar companies1

Intelligence